Miguel Patricio and Albert Bourla lead very different corners of the global economy. Patricio is a Portuguese-born marketer who ran Kraft Heinz, and Bourla is a Greek-born veterinarian who runs Pfizer. Both built international careers that shaped what people eat, drink and take as medicine.
This guide covers age, background, career, awards and net worth for both executives. It relies on company filings, official announcements and credible business reporting. Where a detail is an estimate or unconfirmed, the article says so plainly.
Miguel Patricio and Albert Bourla: 5 Key Facts at a Glance
- Patricio is a native of Portugal who became Kraft Heinz CEO on July 1, 2019.
- Bourla became Pfizer CEO in January 2019, after more than 30 years at the company.
- Patricio stepped down as executive chair on January 1, 2026, and AB InBev’s shareholders appointed him a director on April 29, 2026.
- Bourla holds a veterinary medicine degree and a PhD from Aristotle University of Thessaloniki.
- Neither man’s total net worth is officially disclosed. Only reported share holdings and pay can be verified, so any single wealth figure online is an estimate.
Quick Bio Comparison Table
| Detail | Miguel Patricio | Albert Bourla |
| Age (October 2026) | 59 or 60 (exact birth date not public) | 65 |
| Born | Portugal | Thessaloniki, Greece, October 21, 1961 |
| Nationality | Portuguese | Greek-American |
| Education | Business Administration, Fundação Getulio Vargas, São Paulo | Veterinary medicine degree and PhD, Aristotle University |
| Profession | Executive, marketer, board director | Chairman and CEO of Pfizer |
| 2026 role | Director, AB InBev | Chairman and CEO, Pfizer |
| Net worth | Not officially disclosed | Not officially disclosed |
Patricio’s birth year is listed only as 1966 or 1967, so his age is a range rather than a confirmed number. Bourla’s birthday is October 21, so he turned 65 this week.
Miguel Patricio: Who He Is and What He Is Known For
Patricio holds a business administration degree from Fundação Getulio Vargas in São Paulo. He is known first as a brand builder rather than a financial or operations executive.
He led marketing at Ambev in Brazil from 1999 to 2004, then held zone president and marketing leadership roles at AB InBev from 2005 to 2012. He served as AB InBev’s global chief marketing officer from 2012 to 2018, working on Corona, Budweiser and Stella Artois.
In his final year in that job, AB InBev was the most awarded brand owner at Cannes Lions 2018. That record is the main reason Kraft Heinz hired him as CEO.
Miguel Patricio’s Role and Tenure at Kraft Heinz
- 2019: The board appointed him CEO effective July 1. His predecessor’s tenure had included a $15.4 billion impairment charge, and the SEC had announced an investigation into the company’s accounting and procurement practices.
- 2021 to 2022: He joined the board in May 2021 and became chair in May 2022.
- 2023 to 2024: His time as CEO ran until December 2023, and Carlos Abrams-Rivera replaced him in January 2024.
- September 2025: He became Executive Chair as the board chose to separate Kraft Heinz into two companies.
- January 2026: He stepped down as executive chair but stayed on as a non-employee director. The 2026 proxy statement calls him the retiring Executive Chair.
In total he spent more than six years in top Kraft Heinz leadership roles.
Miguel Patricio’s Approach to Leadership
Patricio led as a marketer. At his appointment he said he would focus on speed, organic growth, brand building and a more consumer-focused company. The board chairman at the time described him as a leader focused on consumer-first marketing, innovation and people development.
His final major decision was the separation plan. He argued that the company’s complexity made it hard to allocate capital and prioritize initiatives.
The plan did not survive his departure. In February 2026 the new CEO paused work on the split and redirected $600 million into marketing, sales and product development. One analyst noted that demand and operating challenges had weakened the case for the original value-unlocking rationale.
That is a business judgment about one plan. It is not a verdict on his whole career, and the split could still return later.
Miguel Patricio vs Albert Bourla Before Fame
Patricio started in marketing. He was a global marketing director at Johnson & Johnson from 1989 to 1995, then moved through Coca-Cola, Philip Morris and Ambev. His early years were spent in consumer brands across Latin America and the United States.
Bourla started in veterinary science. He was born into Thessaloniki’s Sephardic Jewish community, and his parents survived the Holocaust. He joined Pfizer in 1993 as technical director of its animal health division in Greece.
Bourla moved to the United States in 2001 after a promotion. Both men began far from the boardroom and moved through several countries before reaching the top.
Miguel Patricio vs Albert Bourla Social Media Presence
Patricio keeps a low personal profile. His public voice appears mainly in company statements, earnings events and interviews. He is not a prominent online personality.
This article does not link personal accounts for either executive. Many name-based accounts cannot be verified, and fan or impersonation pages are common for well-known executives.
Bourla is far more visible. He wrote the book “Moonshot” about Pfizer’s vaccine race and gives frequent television interviews. That exposure has also brought political criticism. For reliable updates on either man, company filings and official press releases are the safest sources.
Albert Bourla: Who He Is and Why He Matters
Bourla is Chairman and CEO of Pfizer, chair of the Pfizer Foundation and co-chair of the Partnership for New York City. He is a rare CEO who trained as a veterinarian, and he has said artificial intelligence is central to how Pfizer discovers and makes medicines.
He matters because Pfizer’s decisions affect vaccines, cancer care and drug pricing worldwide. Few healthcare executives have had a larger public profile since 2020.
Albert Bourla’s Career Journey at Pfizer
- 1993: Joined Pfizer’s animal health division in Greece.
- 2010 to 2013: Led the Established Products Business Unit.
- 2014 to 2016: Served as group president of vaccines, oncology and consumer healthcare.
- 2016: Became Group President of Innovative Health.
- 2018: Named Chief Operating Officer effective January 1.
- 2019: Promoted to CEO in October 2018, effective January 1, 2019.
- 2020: Named chairman of the boardThe pattern is steady promotion through animal health, vaccines, oncology and then the whole company.
Miguel Patricio vs Albert Bourla Awards and Achievements
Bourla has also appeared on Fortune’s Most Powerful People in Business list and Time’s 100 Most Influential People in Health. This article found no widely documented personal major awards for Patricio, and it does not invent any.
Miguel Patricio vs Albert Bourla Net Worth
Neither executive has published a net worth figure. Their wealth comes mainly from executive pay, stock awards and long-held company shares. The table below uses only disclosed holdings and reported pay.
Share values move daily with stock prices, so these figures will already have shifted. Online estimates for both men vary widely. Some trackers use older or narrower share counts, and many give no method.
Treat any single “net worth” number as an estimate, not a fact. Holdings and pay are verified. Total wealth is not.
Albert Bourla and Pfizer’s Position in 2026
Pfizer is in a transition year. It guided 2026 revenue to $59.5 billion to $62.5 billion, with about $1.5 billion lost to expiring patents. COVID-related sales fell from an estimated $11 billion in 2024 to $6.5 billion in 2025.
The answer is a pipeline rebuild. Pfizer bought obesity biotech Metsera for $10 billion after a bidding war with Novo Nordisk. It plans 10 Phase III trials for the lead drug, aiming for a 2028 launch.
Bourla said new and acquired products grew 22% in the first quarter of 2026. Pfizer expects high single-digit revenue growth for five years starting in 2029. That is a forecast, not a result, and the next two years carry most of the patent risk.
Albert Bourla’s Leadership During the COVID-19 Pandemic
Pfizer delivered a safe and effective COVID-19 vaccine in eight months, working with BioNTech. It also produced the first FDA-authorized oral antiviral treatment.
Bourla had restructured Pfizer shortly after becoming CEO, which helped the company respond when the pandemic arrived. That period defined his public image and lifted Pfizer’s revenue to record levels.
It also made him a political figure. Supporters credit his speed and risk-taking. Critics have questioned vaccine pricing and public messaging.
Miguel Patricio and Albert Bourla Compared
International Business Experience
Patricio worked across Latin America, North America and Asia Pacific. At AB InBev he was president of both Asia Pacific and North America.
Bourla held senior positions in five countries before leading Pfizer from New York. Both men are truly global executives, with careers that crossed several markets and languages.
Length and Stability of Leadership
Patricio was CEO for about four and a half years and chaired the board for several more. Bourla has been CEO for nearly eight years, after three decades inside Pfizer.
Bourla’s tenure is longer and more continuous. Patricio’s CEO term ended in a planned handover, and his flagship plan was paused soon after.
Distinct Industry Expertise
Patricio’s strength is consumer marketing across beer, soft drinks and packaged food. He understands how brands win shelf space and shopper loyalty.
Bourla’s strength is science-led healthcare, from animal health to vaccines and oncology. His decisions depend on clinical data, regulators and long development timelines.
Driving Corporate Transformation
Patricio proposed splitting Kraft Heinz in two. His successor paused it.
Bourla reshaped Pfizer around science. He divested non-science businesses and increased investment in R&D and technology. Pfizer’s $43 billion Biogen deal in 2023 and the Metsera purchase followed.
Why Miguel Patricio and Albert Bourla Matter in 2026
Both executives sit at turning points. Kraft Heinz is in a turnaround under new leadership. Patricio’s governance role has moved to AB InBev’s board, where his four-year term runs to 2030.
Pfizer is racing to replace expiring products under Bourla. Investors, doctors and policymakers watch every pipeline update.
Their stories show two models of global leadership. One is built on brands and consumers, the other on science and capital allocation. Together they explain how very different industries respond to pressure.
Conclusion
Miguel Patricio and Albert Bourla are global business leaders with distinct paths. Patricio rose through marketing, led Kraft Heinz from 2019 to 2023 and now serves on AB InBev’s board. Bourla rose from veterinary medicine to run Pfizer and guide its COVID-19 response.
On age, career and net worth, the verified record is clear for roles, dates and holdings. Total wealth stays undisclosed for both, and online figures should be read as estimates.
For readers tracking Kraft Heinz, AB InBev or Pfizer in 2026, this profile gives the confirmed facts and keeps speculation separate.
Frequently Asked Questions
Who is Miguel Patricio, and what is he known for?
He is a Portuguese-born executive and former Kraft Heinz CEO. He was previously AB InBev’s global chief marketing officer.
Is Miguel Patricio still the CEO of Kraft Heinz in 2026?
No. Steve Cahillane became CEO on January 1, 2026, and Patricio stepped down as executive chair the same day.
Who is Albert Bourla, and what does he do?
He is Chairman and CEO of Pfizer. He led the company’s COVID-19 vaccine effort.
What is Albert Bourla’s educational background?
He earned a veterinary medicine degree and a PhD at Aristotle University of Thessaloniki.
When did Albert Bourla become CEO of Pfizer?
He became CEO on January 1, 2019, and chairman in 2020.
Which companies has Miguel Patricio worked for or been associated with?
Johnson & Johnson, Coca-Cola, Philip Morris, Ambev, AB InBev and Kraft Heinz. He joined AB InBev’s board in April 2026.